It would be interesting to investigate the impact of other appetite-suppressing T2D drugs on Lac-Phe levels, focusing on GLP-1 receptor agonists, dual GIP-GLP-1 receptor agonists and triple glucagon-GIP-GLP-1 agonists in development21. The gene discussed is GIP; the disease is type 2 diabetes mellitus.